Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Acta Gastroenterol Belg ; 81(3): 373-380, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30350524

RESUMEN

BACKGROUND: We aimed to describe the natural course of inflam-matory bowel disease (IBD) in adult Turkish patients during the past decade. METHODS: We performed a retrospective investigation in total 508 patients with IBD between 2006 and 2016. The severity of IBD was assessed by the need for hospitalization, biological therapy and surgery. The study consisted of 304 (59.8%) patients with UC, 180 (35.4%) with CD and 24 (4.7%) IBD unclassified patients. The ratio of severe disease for both CD and UC was as follows: hospitalization in 71 (39.4%) and 37 (12.2%), biological therapy received in 20 (11.1%) and 3 (1.0%), and surgery in 23 (12.8%) and 2 (0.7%) respectively. Patients were divided into two groups based on the date of disease onset. Earlier group includes the patients followed-up between 2006-2011 and later group, between 2011-2016. Our results revealed that the proportion of patients receiving biological therapies was significantly higher and the rate of surgery was significantly lower in the later group compared to the earlier group (14.5% to 0%, 9.4 to 23.8, respectively). The hospitalization rate was lower in the later group compared to earlier group but did not reach a significant difference (37.7% to 45.2% respectively). CONCLUSIONS: The course of IBD in Turkish patients appears to be between that of Europe and Asia. In patients with CD, proportion of patients receiving biologic therapy has increased while rate of surgery has decreased.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Antirreumáticos/uso terapéutico , Colitis Ulcerosa/terapia , Enfermedad de Crohn/terapia , Procedimientos Quirúrgicos del Sistema Digestivo/tendencias , Fármacos Gastrointestinales/uso terapéutico , Hospitalización/tendencias , Adalimumab/uso terapéutico , Adulto , Azatioprina/uso terapéutico , Productos Biológicos/uso terapéutico , Fumar Cigarrillos/epidemiología , Colitis Ulcerosa/epidemiología , Enfermedad de Crohn/epidemiología , Femenino , Glucocorticoides/uso terapéutico , Humanos , Enfermedades Inflamatorias del Intestino/epidemiología , Enfermedades Inflamatorias del Intestino/terapia , Infliximab/uso terapéutico , Masculino , Mesalamina/uso terapéutico , Metotrexato/uso terapéutico , Persona de Mediana Edad , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Distribución por Sexo , Sulfasalazina/uso terapéutico , Turquía/epidemiología , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...